LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.